The purpose of this study is to evaluate the effect of pulse widths \<500 μsec and \>1000 μsec on clinical outcomes during a temporary SCS trial.
The proposed study is a prospective, multi-center, two-arm, randomized, crossover design to be conducted at up to 10 sites. The study will enroll up to 100 subjects in order to include up to 10 subjects in the study per site. Subjects selected to participate in the trial have back and/or leg pain, have been evaluated as a candidate for SCS and have agreed to undergo a temporary SCS trial using the Algovita® system with percutaneous leads. Each subject will be followed during the trial period of approximately 7+/-2 days. The study will end when the last subject has completed the trial period and exited. The expected enrollment period for this study is approximately six months. After exit from the clinical study, subjects will continue to be followed by their physician per usual care. All device and procedure-related AEs will be collected and reported per the study protocol.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
OTHER
Masking
NONE
Enrollment
15
The Algovita™ SCS system is indicated as an aid in the management of chronic intractable pain of the trunk and/or limbs, including unilateral or bilateral pain associated with failed back surgery syndrome, intractable low back pain and leg pain.
The Ohio Pain Clinic
Centerville, Ohio, United States
Effect of Pulse Widths on Pain Clinical Outcomes
To evaluate the effect of conventional pulse widths \<500 μsec and pulse widths \>1000 μsec on clinical outcomes during temporary trial as measured by patient defined pain maps.
Time frame: For 7 days following intervention
Change in Targeted Pain
To evaluate the effect of conventional pulse widths \<500μsecand pulse widths and \>1000μsecon clinical outcomes during temporary trial as measured by the number of participants that reported significant change in targeted pain compared to baseline using the NRS at the end of the trial period.
Time frame: For 7 days following intervention
Distribution of Paesthesia
At end of each arm, subjects will be asked to complete a diagram that shows distribution of paresthesia.
Time frame: For 7 days following intervention
Research Participant Program Preference
At the end of the trial period, subjects will be asked to select their favorite program.
Time frame: For 7 days following intervention
Quality of Pain Relief
At the end of the trial period, subjects will be asked to rate the quality of the pain relief achieved during the trial (from either arm) using the following ordinal scale; Excellent, Very Good, Good, Fair or Poor
Time frame: For 7 days following intervention
Research Participant Pain Relief Satisfaction
At the end of the trial period, subjects will be asked to rate their overall satisfaction with the pain relief achieved during the trial (from either arm) using the following ordinal scale; Very Satisfied, Satisfied, Neither Satisfied nor Unsatisfied, Unsatisfied or Very Unsatisfied
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: For 7 days following intervention
≥ 50% Pain Relief
Number of patients who achieved ≥ 50% pain relief during the trial (from either arm)
Time frame: For 7 days following intervention
Rate of AEs
Rate of device-related and/or procedure-related AEs from SCS implant through study completion or study exit.
Time frame: For 7 days following intervention